NO20034648L - Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander - Google Patents

Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander

Info

Publication number
NO20034648L
NO20034648L NO20034648A NO20034648A NO20034648L NO 20034648 L NO20034648 L NO 20034648L NO 20034648 A NO20034648 A NO 20034648A NO 20034648 A NO20034648 A NO 20034648A NO 20034648 L NO20034648 L NO 20034648L
Authority
NO
Norway
Prior art keywords
hydroxycyclyloxy
thioxy
hydroxytryptamine
ligands
aminobenzazole
Prior art date
Application number
NO20034648A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034648D0 (no
Inventor
Ping Zhou
Boyd Lynn Harrison
Yanfang Li
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20034648D0 publication Critical patent/NO20034648D0/no
Publication of NO20034648L publication Critical patent/NO20034648L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20034648A 2001-04-20 2003-10-17 Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander NO20034648L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28564301P 2001-04-20 2001-04-20
PCT/US2002/012415 WO2002085892A1 (en) 2001-04-20 2002-04-19 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (2)

Publication Number Publication Date
NO20034648D0 NO20034648D0 (no) 2003-10-17
NO20034648L true NO20034648L (no) 2003-11-20

Family

ID=23095111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034648A NO20034648L (no) 2001-04-20 2003-10-17 Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander

Country Status (17)

Country Link
US (2) US6815456B2 (ja)
EP (1) EP1385842A1 (ja)
JP (1) JP4323810B2 (ja)
KR (1) KR20030088508A (ja)
CN (1) CN1293072C (ja)
AR (1) AR035235A1 (ja)
BR (1) BR0209056A (ja)
CA (1) CA2444095A1 (ja)
EA (1) EA200301142A1 (ja)
EC (2) ECSP034811A (ja)
HU (1) HUP0303958A2 (ja)
IL (1) IL158445A0 (ja)
MX (1) MXPA03009476A (ja)
NO (1) NO20034648L (ja)
PL (1) PL367297A1 (ja)
WO (1) WO2002085892A1 (ja)
ZA (1) ZA200309004B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033529A3 (cs) * 2001-06-07 2004-04-14 F. Hoffman-La Roche Ag Nové deriváty indolu s afinitou k receptoru 5-HT6
CN1701477A (zh) * 2002-02-13 2005-11-23 皇家飞利浦电子股份有限公司 集成半导体光学设备以及制造该设备的方法和装置
JP4390698B2 (ja) * 2002-06-05 2009-12-24 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ障害の処置のための５−ｈｔ６レセプターモジュレーターとしての１−スルホニル−４−アミノアルコキシインドール誘導体
EA011009B1 (ru) 2003-01-14 2008-12-30 Арена Фармасьютикалз Инк. 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
EP1592683A2 (en) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
DE102004010132A1 (de) * 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
DE602005011844D1 (de) * 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
DOP2006000010A (es) * 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
CA2594487A1 (en) * 2005-01-19 2006-07-27 Matthias Heinrich Nettekoven 5-aminoindole derivatives
CN101282938A (zh) * 2005-08-15 2008-10-08 惠氏公司 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物
JP2009504738A (ja) * 2005-08-15 2009-02-05 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのアジニル−３−スルホニルインダゾール誘導体
BRPI0709718A2 (pt) * 2006-04-05 2011-03-29 Wyeth Corp composto; método para tratamento de um transtorno do sistema nervoso central relacionado a ou afetado pelo receptor 5-ht6 em um paciente necessitado; composição farmacêutica; e proceso para a preparação do composto
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
CN101432269A (zh) * 2006-06-01 2009-05-13 惠氏公司 作为5-羟色胺-6配体的1-磺酰基吲唑基胺和1-磺酰基吲唑基酰胺衍生物
US20090023925A1 (en) * 2007-06-28 2009-01-22 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
WO2009034581A1 (en) * 2007-09-11 2009-03-19 Suven Life Sciences Limited Substituted indolyl compounds and their use as 5-ht6 ligands
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
AU2015286049B2 (en) * 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CN111233736B (zh) * 2020-03-16 2021-07-16 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
WO2024032530A1 (zh) * 2022-08-11 2024-02-15 江苏恩华药业股份有限公司 芳杂环并环己烷基氨基烷基哌啶衍生物、制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH0940646A (ja) 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
WO1998050346A2 (en) * 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
WO2001002356A1 (fr) 1999-07-01 2001-01-11 Sankyo Company, Limited Dérivés d'indoline ou tétrahydroquinoline
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
KR20030062442A (ko) * 2000-12-22 2003-07-25 와이어쓰 5-하이드록시트립타민-6-리간드로서의 헤테로사이클인다졸및 아자인다졸 화합물
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
EP1592683A2 (en) * 2003-02-14 2005-11-09 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
MXPA03009476A (es) 2004-02-12
US20050065186A1 (en) 2005-03-24
WO2002085892A1 (en) 2002-10-31
HUP0303958A2 (hu) 2004-04-28
NO20034648D0 (no) 2003-10-17
CN1518547A (zh) 2004-08-04
ECSP034811A (es) 2003-12-01
EA200301142A1 (ru) 2004-02-26
IL158445A0 (en) 2004-05-12
CN1293072C (zh) 2007-01-03
US20030069278A1 (en) 2003-04-10
US6815456B2 (en) 2004-11-09
AR035235A1 (es) 2004-05-05
BR0209056A (pt) 2004-08-10
CA2444095A1 (en) 2002-10-31
ECSP034810A (es) 2003-12-01
EP1385842A1 (en) 2004-02-04
ZA200309004B (en) 2005-02-21
PL367297A1 (en) 2005-02-21
KR20030088508A (ko) 2003-11-19
JP4323810B2 (ja) 2009-09-02
JP2004526787A (ja) 2004-09-02

Similar Documents

Publication Publication Date Title
NO20034648L (no) Hydroksycyklyloksy-, tioksy- og -aminobenzazol-derivater som 5-hydroksytryptamin-6-ligander
DK1355904T3 (da) Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander
DK1353904T3 (da) 1-Aryl- eller 1-alkylsulfonylbenzazolderivater som 5-hydroxytryptamin-6-ligander
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20031977D0 (no) 1-aryl- eller 1-alkylsulfonyl-heterocyklylbenzazoler som 5- hydroksytryptamin-6-ligander
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
NO20042279L (no) Kinazolinderivater som antitumormidler
NO20042288L (no) Kinazolinderivater som antitumormidler
MXPA03008590A (es) Derivados del factor vii de coagulacion.
ITTO20010940A0 (it) ,,sedia,,
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20041316L (no) Tiofen- og tiazoisulfonamider som antineoplastiske midler
DK1355900T3 (da) Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
NO20034647L (no) Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander
ZA200404807B (en) Imidazoquinoline derivatives.
NO20024502D0 (no) 4-okso-1,4-dihydro-3-cinnolinkarboksamider som antivirale midler
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DK1140851T3 (da) 4-Oxo-1,4-dihydro-3-quinolincarboxamider som antivirale midler
DK1177185T3 (da) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
ES1048795Y (es) Embalaje perfeccionado.
DK1287001T3 (da) Thiophenderivater, der er egnede som anticancermidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application